Intracerebral hemorrhage (ICH) is an important cause of stroke-related death and disability. Intracerebral hemorrhage accounts for 10 to 15% of all strokes in the United States with an incidence of 12 to 15 cases per 100,000 per year.
1,2 The incidence is higher in Asian countries, at 20 to 30% of all strokes. 3 Mortality is almost 50% at 30 days, and half of these deaths occur within the first 24 hours. 1 Although no intervention tested in clinical trials to date has significantly demonstrated improved functional outcome following ICH, recently completed and ongoing trials may have a direct impact on the acute care of ICH patients. In this review, we discuss acute management of ICH in light of recently completed and ongoing ICH clinical trials.
Prognosis in Intracerebral Hemorrhage
An important prognostic factor in ICH is the presenting hematoma volume and subsequent hematoma expansion. Hematoma expansion occurs in upwards of 40% of ICH patients, 4,5 typically occurs within the first few hours, and portends neurologic deterioration, poorer functional outcome, and increased mortality. Each 10% increase in hematoma size from baseline has been associated with a 5% increase in mortality and 16% chance of worse functional outcome. 6 Unfortunately, trials of hemostatic agents for ICH (discussed in more detail below) have not shown improved functional outcomes.
7,8
Concurrent intraventricular hemorrhage (IVH) is another factor that has been associated with worse outcome after ICH. Intracerebral hemorrhage may lead to obstructive hydrocephalus causing acute intracranial hypertension that may result in herniation syndromes. Mortality rates of 50 to 80% have been reported in ICH patients with IVH. improve past the 6-month mark and reports of early morbidity and mortality may misrepresent potential outcomes. 15 
Acute Management of Intracerebral Hemorrhage
Intracerebral hemorrhage is an emergency. The acute clinical presentation depends on the location of the lesion within the brain. A sudden focal neurologic deficit, change in consciousness, headache, or vomiting are common presentations. A computed tomography (CT) scan or magnetic resonance imaging (MRI) is required to confirm a diagnosis of ICH. Care should always begin with airway stabilization, breathing, and circulation (ABCs). Specifically, many patients require active airway management with endotracheal intubation and mechanical ventilation secondary to their depressed mental status. The head of the bed should be elevated to 30 degrees at all times, and the neck kept in a midline position. Adequate analgesia and sedation should be provided. Other specific measures such as blood pressure management are crucial as well. Acute emergency department (ED) interventions that can minimize bleeding are critical for improved outcomes. These are discussed further below and in addition to the ABCs include timely diagnosis, blood pressure management, and reversal of anticoagulation.
Imaging
Initial imaging and diagnosis of ICH is almost always made on a noncontrast head CT. Addition of CT angiography (CTA) may reveal a "spot sign," a hyperdensity within the hematoma corresponding to contrast extravasation, which has been associated with subsequent hematoma expansion. [16] [17] [18] In the largest prospective observational study published to date, 30% of 268 ICH patients with ICH volume less than 100 mL who underwent CTA within 6 hours of symptom onset had a spot sign. 18 Of these, 61% experienced hematoma expansion compared with 22% of patients who had no spot sign. Sensitivity of the spot sign for predicting hematoma expansion was 51% and specificity was 85%.
18
Early CTA may also reveal secondary causes of ICH such as arteriovenous malformations and aneurysms. Magnetic resonance imaging (MRI), MR angiography (MRA), catheter angiography also play a significant role in identifying secondary causes of ICH and may be essential prior to enrolling patients in clinical trials testing administration of rt-PA for hastening clot resolution. The most recent American Stroke Association (ASA) guidelines do not specify which ICH patients may benefit from vascular imaging for evaluation of secondary causes.
1 However, recent clinical experience suggests such imaging may be warranted in more patients than currently recognized, particularly in the young (►Fig. 1). 
Blood Pressure Control

Hemostatics
Various hemostatic agents have been and are currently being tested as therapies for the management of ICH. One hemostatic agent of high interest is recombinant activated factor VII (rFVIIa). rFVIIa has been proven to significantly reduce hematoma expansion in phase IIb (n ¼ 339) 7 and phase III (n ¼ 841) 8 trials when given within 4 hours of symptom onset. Unfortunately, clinical efficacy in terms of improved outcomes was not demonstrated in those trials. A proposed explanation for this lack of efficacy for improving outcomes despite reducing hematoma expansion was the inclusion of an unselected patient population. Particularly, rFVIIa treatment was associated with an 20% absolute increase in ischemic strokes and myocardial infarction in the phase III trial. 23 Thus, exposure of patients who were not bound to experience hematoma expansion to this risk may have blunted any benefits from reducing hematoma expansion in patients who experienced expansion. 8 Patients with large hematomas were also included although they were bound to have a poor outcome regardless of hematoma expansion. As such, it has been suggested that patients aged 70 years or younger, ICH volume < 60 mL with minimal IVH and treated within 2.5 hours may be a subset of patients who would benefit from rFVIIa. 24 Patient selection based on the spot sign may also select those patients most likely to experience hematoma expansion. Two ongoing trials are using early CTA to select ICH patients for treatment with rFVIIa. The Spot Sign for Predicting & Treating ICH Growth (STOP-IT) study is an ongoing phase II, randomized, multicenter, double-blind, placebocontrolled trial with the primary goals of (1) determining the sensitivity and specificity of the CTA spot sign for predicting hematoma expansion, (2) determining the feasibility of using CTA to identify ICH patients at high risk of hematoma expansion and to select spot-positive patients for randomization to treatment with rFVIIa or placebo, and (3) determining the rate of hematoma expansion among spot-positive patients at 24 hours. The planned enrollment is for 184 total patients. 25 The Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT) study is also an ongoing, phase II, randomized, multicenter, double-blind, placebo-controlled trial with similar goals of randomizing spot-positive ICH patients to treatment with rFVIIa to those treated with placebo. The planned enrollment size is 110 patients in Canada.
25
Anticoagulant-Related Intracerebral Hemorrhage
About one in five cases of ICH are anticoagulant related.
26
Warfarin remains the most commonly used oral anticoagulant, and interventions that reverse anticoagulation due to warfarin are crucial. Options for reversal of anticoagulation due to warfarin include fresh frozen plasma (FFP), vitamin K, prothrombin complex concentrates (PCCs), and rfVIIa, alone or in combination.
27
Fresh frozen plasma and vitamin K remain the most commonly used reversal agents. Delays in administration of FFP have been reported and every 30-minute delay in administration of FFP is associated with a 20% reduction in successful INR correction by 24 hours after presentation. 28 Vitamin K should be administered to all patients with warfarin-related ICH, but it is not sufficiently effective in a short period to suffice as the only treatment for ICH. Prothrombin complex concentrates may be classified as three factor (sufficient levels of factors II, IX, and X, and low levels of factor VII) or four factor (sufficient levels of factors II, VII, IX, and X, as well as proteins C and S). Prothrombin complex concentrates are more effective than FFP in rapidly reversing anticoagulation due to warfarin, 29 require less volume infusion, and can be delivered rapidly. As such, in addition to vitamin K administration, four-factor PCCs is recommended over FFP for patients with major bleeding. 27 Four-factor PCCs had been unavailable in the United States until the U.S. Food and Drug Administration (FDA) approved Kcentra (CSL Behring GmbH, Marburg, Germany) in May 2013. Given the lifethreatening consequence of delays in reversal of anticoagulation in patients with warfarin-related ICH, we believe fourfactor PCCs should be first-line therapy in addition to administration of vitamin K and additional FFP as needed. Novel anticoagulant agents including direct thrombin inhibitors such as dabigatran and factor Xa inhibitors such as rivaroxaban and apixaban have recently been approved for treatment of atrial fibrillation and venous thromboembolism. [30] [31] [32] [33] Although case vignettes of ICH and other major bleeding associated with these agents have been published, no proven reversal regimens exist. As such, options for treating ICH related to these novel anticoagulants are FFP, PPCs, and rFVIIa.
Surgical Management
Surgical management of ICH should be discussed in terms of approach (craniotomy/craniectomy vs. minimally invasive approaches) and ICH location (supra-or infratentorial location). Emergent craniectomy may be life-saving in patients with posterior fossa ICH, and surgery is recommended in patients with posterior fossa hemorrhages larger than 3 cm in diameter, brainstem compression, or hydrocephalus from ventricular obstruction. saving surgery, there is little controversy with this recommendation and treatment approach. In the context of the STICH II results discussed below, it remains unclear whether craniotomy/craniectomy is beneficial in supratentorial ICH. Minimally invasive hematoma evacuation after ICH offers the benefit of removal of offending factors in blood that may cause secondary injury without the morbidity associated with craniotomy. The largest trial published to date randomized 377 patients with small basal ganglia ICH (25-40 mL) to craniopuncture followed by urokinase and clot aspiration versus medical therapy alone. 34 At 90 days, there was no significant difference in mortality (6.7% vs. 8.8%, p ¼ 0.44), and the medical therapy group was more likely to be dependent (modified Rankin score 3-6) (63% vs. 41%, p < 0.01).
34
The MISTIE III and CLEAR III trials will confirm whether this approach is associated with improved long-term outcomes in treated patients.
Neuroprotective Strategies
In addition to direct tissue destruction and mass effect on adjacent tissues, ICH may trigger many deleterious inflammatory cascades. These include tissue necrosis, cellular apoptosis, and edema. Various neuroprotective approaches are being evaluated for efficacy in reducing secondary injury after ICH. To our knowledge, none are currently mature enough for phase III clinical trial evaluation.
Phase III Clinical Trials in Intracerebral Hemorrhage Clinical Trials Published in 2013
Two critical phase III clinical trials of ICH were published in the past year: (1) rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT2) 35 and (2) early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral hematomas (STICH II), a randomized trial.
36
INTERACT2 randomized 2839 patients with spontaneous ICH diagnosed on CT or MRI who presented within 6 hours to an intensive treatment to lower blood pressure (target systolic of < 140 mm Hg within 1 hour) or current guidelinerecommended treatment (target systolic level of < 180 mm Hg). Patients were eligible if they had a systolic blood pressure (SBP) between 150 and 220 mm Hg and had no contraindication to blood pressure lowering. Antihypertensive medication choices were at the discretion of the treating physician. Of 2,794 patients for whom the primary outcome of death or major disability (defined as a score of 3-6 on the modified Rankin scale) was available at 90 days, 52% in the intensive group versus 56% in the standard treatment group had the primary outcome (odds ratio ¼ 0.87; 95% CI ¼ 0.75-1.01, p ¼ 0.06). The authors concluded that intensive blood pressure reduction in acute ICH was safe, but did not significantly reduce death or major disability.
35
The STICH II trial hypothesized that early surgery could improve outcome in conscious patients in whom there was a superficial ICH of 10 to 100 mL and no evidence of IVH. STICH II randomized 601 patients from 78 centers in 27 countries to early surgery (within 12 hours of ictus) or initial conservative treatment. The primary outcome was a prognosis-based favorable or unfavorable outcome based on the Extended Glasgow Outcome Scale (GOSE) at 6 months after randomization. Forty-one percent (123 out of 297) of patients in the early surgery group had a favorable outcome at 6 months compared with 38% (108 out of 286) of patients in the initial conservative treatment group (OR ¼ 0.86, 95% CI ¼ 0.62-1.20, p ¼ 0·367). Notably, 21% of the initial conservative treatment group in STICH II had surgery, thereby potentially blunting any treatment effect that may have been observed. Ultimately, it remains unclear what subgroup of ICH patients would benefit from surgery although ongoing studies may better define this.
36
Ongoing Phase III ICH Clinical Trials
To our knowledge, there are three ongoing phase III acute interventional trials in ICH. The Antihypertensive Treatment of Cerebral Hemorrhage (ATACH) 2 trial is randomizing ICH patients to a goal SBP of < 140 mm Hg versus < 180 mm Hg within 3.5 hours of symptom onset. Blood pressure targets are to be maintained for 24 hours after randomization. Both arms of the trial receive nicardipine in standard dosing regimens established per trial protocol.
37 Labetalol may also be used if maximum amounts of nicardipine are used. Given the relatively delayed onset to initiation of therapy (< 6 hours), the multiple medications used and the difference in time from randomization to initiation of antihypertensive therapy between the treatment groups in INTERACT2, 35 ATACH 2 should provide further data on the safety and efficacy of ultraearly (< 3.5 hours) rapid reduction of blood pressure using a single antihypertensive agent after ICH. With a planned enrollment of 500 ICH patients with IVH, the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) III trial is randomizing ICH patients who require an EVD for obstructive hydrocephalus due to third or fourth ventricular blood to recombinant tissue plasminogen activator (rt-PA) versus placebo for resolving the IVH. Treatment must begin within 72 hours of the diagnostic CT scan. In addition to third or fourth ventricular obstruction, eligible patients must have < 30 mL of ICH. The primary outcome measure is the modified Rankin scale score at 180 days.
38
The Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation (MISTIE) Phase III trial is a randomized clinical trial of minimally invasive surgery plus rt-PA versus medical therapy alone after ICH. Eligible patients must have supratentorial ICH 30 mL, symptom onset within 24 hours of diagnostic CT and initiation of treatment from 12 to 72 hours of the diagnostic CT, with the first dose given within 76 hours of the diagnostic CT. The primary efficacy outcome measure is a 12% increase in the proportion of rt-PA treated patients with a modified Rankin score of 0 to 3 compared with medically treated patients at 180 days. The primary safety outcome measure is the rate of mortality, rebleeding, and infection at 30 days. 
Conclusions
Intracerebral hemorrhage remains a challenging clinical and public health problem. Fortunately, recently completed and ongoing acute clinical trials have and will meaningfully impact its clinical management. Although no trials to date have shown a definite improvement in functional outcomes with a given intervention, recent trials have informed blood pressure management and the need for surgery after acute ICH. Ongoing trials should add to current knowledge and are promising for establishing the efficacy of the medical and surgical interventions being tested.
